CG Oncology (NASDAQ:CGON) Trading Down 7.5% – Here’s What Happened

CG Oncology, Inc. (NASDAQ:CGON)’s stock price fell 7.5% on Thursday . The stock traded as low as $69.00 and last traded at $68.4450. 431,027 shares changed hands during trading, a decline of 65% from the average session volume of 1,220,286 shares. The stock had previously closed at $74.00.

More CG Oncology News

Here are the key news stories impacting CG Oncology this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating on CG Oncology and maintained a $100 price target, suggesting analysts still see meaningful upside from current levels.
• Positive Sentiment: The brokerage also lifted its FY2030 earnings estimate, indicating confidence in the company’s longer-term commercial potential.
• Neutral Sentiment: CG Oncology presented at the Bank of America Global Healthcare Conference, which kept investor attention on the story but did not include any clearly market-moving new data. Article Title
• Negative Sentiment: HC Wainwright cut its earnings estimates for Q2 2026, Q3 2026, Q4 2026, FY2026, FY2027, and FY2028, reinforcing the view that losses may persist longer than previously expected.
• Negative Sentiment: The updated forecasts point to larger near-term EPS losses, which can weigh on biotech stocks when investors focus on the path to profitability.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on CGON shares. JPMorgan Chase & Co. lifted their target price on shares of CG Oncology from $91.00 to $96.00 and gave the stock an “overweight” rating in a research report on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CG Oncology in a research note on Monday, April 20th. Truist Financial reiterated a “buy” rating and issued a $82.00 price target (up from $77.00) on shares of CG Oncology in a research report on Thursday. Wall Street Zen downgraded shares of CG Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, April 25th. Finally, Piper Sandler upped their price target on shares of CG Oncology from $55.00 to $70.00 and gave the company an “overweight” rating in a research report on Friday, January 16th. Eleven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $81.73.

CG Oncology Price Performance

The stock has a market cap of $6.12 billion, a price-to-earnings ratio of -29.53 and a beta of 0.41. The firm’s fifty day moving average price is $66.77 and its two-hundred day moving average price is $53.68.

CG Oncology (NASDAQ:CGON) last posted its earnings results on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.13). The company had revenue of $1.08 million for the quarter, compared to the consensus estimate of $0.45 million. On average, equities research analysts anticipate that CG Oncology, Inc. will post -2.77 earnings per share for the current year.

Insider Buying and Selling at CG Oncology

In related news, Director James Mulay sold 15,600 shares of the stock in a transaction dated Friday, April 17th. The stock was sold at an average price of $73.01, for a total transaction of $1,138,956.00. Following the sale, the director owned 15,600 shares of the company’s stock, valued at approximately $1,138,956. This represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 4.80% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in CGON. NFSG Corp purchased a new stake in shares of CG Oncology during the 1st quarter valued at $34,000. Whittier Trust Co. of Nevada Inc. bought a new stake in shares of CG Oncology in the 4th quarter valued at about $27,000. Strengthening Families & Communities LLC purchased a new stake in CG Oncology during the 3rd quarter valued at about $40,000. Comerica Bank boosted its holdings in CG Oncology by 100.4% during the 4th quarter. Comerica Bank now owns 1,028 shares of the company’s stock valued at $43,000 after acquiring an additional 515 shares during the period. Finally, Fifth Third Bancorp bought a new position in shares of CG Oncology in the first quarter worth approximately $74,000. Institutional investors own 26.56% of the company’s stock.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.